GlassScriptPhysician profile
Sudhathi Chennuru
NPI 1689740326
$1,076.27
in general payments reported to CMS, 2019-2025
24 companies · $49.08 in 2025
The $49.08 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $16.14 · 2021: $35.85 · 2022: $239 · 2023: $463 · 2024: $168 · 2025: $49.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $128.44 | 2022-2025 | |
| Genzyme Corporation | $112.23 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $110.94 | 2022-2024 | Keytruda, Lynparza |
| Exelixis INC. | $79.85 | 2019 | |
| Seagen INC. | $64.15 | 2023 | Padcev, Adcetris, Tukysa |
| Amgen INC. | $55.00 | 2022 | |
| Janssen Biotech, INC. | $47.19 | 2022-2024 | Tecvayli |
| Astrazeneca Pharmaceuticals LP | $41.54 | 2022-2023 | Tagrisso |
| Taiho Oncology, INC. | $41.02 | 2022-2023 | |
| Eisai INC. | $39.57 | 2022-2023 | |
| Gilead Sciences, INC. | $38.95 | 2021-2024 | |
| Kite Pharma, INC. | $36.22 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2023 | Alunbrig |
| Regeneron Healthcare Solutions, INC. | $33.33 | 2023 | Libtayo |
| Genmab U.S., INC. | $32.65 | 2024 | Epkinly |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $26.58 | 2022 | |
| Pfizer INC. | $26.13 | 2019 | |
| Jazz Pharmaceuticals INC. | $25.41 | 2023 | |
| Sumitomo Pharma America, INC. | $25.16 | 2025 | Orgovyx |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Sobi, INC | $23.26 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2020 | |
| Pharming Healthcare, INC. | $14.49 | 2023 | Ruconest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhathi Chennuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.